Question 42

Carbamazepine has a narrow therapeutic index and requires serum concentrations to be monitored to prevent harm.

Carbamazepine is known for its narrow therapeutic index, which necessitates the monitoring of serum concentrations to avoid toxicity and ensure effective dosing. This characteristic is essential in clinical settings to prevent adverse effects and manage therapeutic efficacy.

A) Carvedilol

Carvedilol does not have a narrow therapeutic index compared to other medications. It is primarily used as a beta-blocker for hypertension and heart failure, and while monitoring may be beneficial, it is not typically required to prevent harm from this medication.

B) Citalopram

Citalopram, an antidepressant, does not possess a narrow therapeutic index. While there are guidelines for monitoring due to potential side effects, especially in high doses, it is not as critical as with medications like carbamazepine, which require more stringent monitoring.

C) Clindamycin

Clindamycin is an antibiotic that does not have a narrow therapeutic index. It is generally considered safe within its prescribed dosage, and routine serum concentration monitoring is not necessary to prevent harm, unlike carbamazepine.

D) Carbamazepine

Carbamazepine is well-documented as a medication with a narrow therapeutic index. It is crucial to monitor serum levels to avoid toxicity and ensure therapeutic effectiveness, making it the correct choice in this context.

Conclusion

Carbamazepine stands out as the medication with a narrow therapeutic index, necessitating careful serum concentration monitoring to prevent adverse effects. In contrast, the other options—carvedilol, citalopram, and clindamycin—do not require such stringent monitoring, confirming that they are not suitable answers for this question.